Alnylam Pharmaceuticals
(NASDAQ) ALNY
Alnylam Pharmaceuticals Financials at a Glance
Market Cap
$40.85B
Revenue (TTM)
$3.71B
Net Income (TTM)
$313.75M
EPS (TTM)
$2.26
P/E Ratio
136.48
Dividend
$0.00
Beta (Volatility)
0.87 (Low)
Dividend
$0.00
Beta (Volatility)
0.87 (Low)
Price
$328.50
Volume
62,998
Open
$312.06
Price
$328.50
Volume
62,998
Open
$312.06
Previous Close
$328.50
Daily Range
$312.06 - $329.48
52-Week Range
$205.87 - $495.55
Dividend
$0.00
Beta (Volatility)
0.87 (Low)
Price
$328.50
Volume
62,998
Open
$312.06
Previous Close
$328.50
Daily Range
$312.06 - $329.48
52-Week Range
$205.87 - $495.55
ALNY News
ALNY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Alnylam Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
2,500
CEO
Yvonne L. Greenstreet, MD, MBA
Website
www.alnylam.comHeadquarters
Cambridge, MA 02142, US
ALNY Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
14%
Net Income Margin
8%
Return on Equity
73%
Return on Capital
14%
Return on Assets
6%
Earnings Yield
0.73%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$40.85B
Shares Outstanding
132.62M
Volume
63.00K
Short Interest
0.00%
Avg. Volume
1.36M
Financials (TTM)
Gross Profit
$3.04B
Operating Income
$501.58M
EBITDA
$557.24M
Operating Cash Flow
$524.08M
Capital Expenditure
$58.70M
Free Cash Flow
$465.38M
Cash & ST Invst.
$2.91B
Total Debt
$1.28B
Alnylam Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.10B
+84.9%
Gross Profit
$829.31M
+69.1%
Gross Margin
75.60%
N/A
Market Cap
$40.85B
N/A
Market Cap/Employee
$18.32M
N/A
Employees
2,230
N/A
Net Income
$186.42M
+322.6%
EBITDA
$145.22M
+203.1%
Quarterly Fundamentals
Net Cash
$1.63B
+3432.5%
Accounts Receivable
$777.57M
+91.8%
Inventory
$82.72M
+5.4%
Long Term Debt
$1.23B
-52.4%
Short Term Debt
$45.52M
-70.6%
Return on Assets
6.32%
N/A
Return on Invested Capital
14.33%
N/A
Free Cash Flow
$140.26M
+235.2%
Operating Cash Flow
$163.56M
+272.8%